Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019049112) FORMULATION OF RESINIFERATOXIN
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/049112 International Application No.: PCT/IB2018/056944
Publication Date: 14.03.2019 International Filing Date: 11.09.2018
IPC:
A61K 9/00 (2006.01) ,A61K 9/08 (2006.01) ,A61K 31/357 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
08
Solutions
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
357
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
Applicants:
SORRENTO THERAPEUTICS, INC. [US/US]; 4955 Directors Place San Diego, California 92121, US
Inventors:
JONES, Bryan; US
NAHAMA, Alexis; US
Agent:
HERRITT, Danielle; US
Priority Data:
62/556,82411.09.2017US
Title (EN) FORMULATION OF RESINIFERATOXIN
(FR) FORMULATION DE RÉSINIFÉRATOXINE
Abstract:
(EN) Disclosed herein are safer formulations of resiniferatoxin (RTX) for intrathecal, intraganglionic intraarticular and pericardial administration. More specifically, there is disclosed alcohol-free formulations of RTX comprising a solubilizing component, a monosaccharide or sugar alcohol, a saline buffer, and RTX, and having narrow ranges for pH range and specific gravity.
(FR) L'invention concerne des formulations plus sûres de résinifératoxine (RTX) pour administration intrathécale, intraganglionnaire, intraarticulaire et péricardique. Plus spécifiquement, l'invention concerne des formulations sans alcool de RTX comprenant un composant de solubilisation, un monosaccharide ou un alcool de sucre, un tampon salin et de la RTX, lesquelles formulations présentent des plages étroites d'intervalle de pH et de densité spécifique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)